They help people lower their blood sugar, lose weight, and even reduce the risk of heart problems in some patients
It increases hyaluronic acid production by up to 800%, and stimulates the production of Collagen Types I, III, and VI, supporting improved skin elasticity and healthy cell turnover
Clinically proven 9 lbs average weight loss in 90 days*
Trials such as TOPCAT and PARAGON-HF failed to meet hospitalization reduction primary endpoints in patients with HFpEF.(5,6) However, the EMPEROR-Preserved and DELIVER trials led the ACC/AHA/HFSA to recommend the sodium glucose-cotransporter 2 (SGLT2) inhibitors, empagliflozin and dapagliflozin, for hospitalization reduction in HFpEF.(7-9) Semaglutides Role in HFpEF Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, and slows gastric emptying.(10) GLP-1 RAs, including liraglutide, dulaglutide, and semaglutide significantly improve glycemic control, promote weight loss, and reduce atherosclerotic cardiovascular and renal risk.(11) Among the approved GLP-1 RAs in the United States, semaglutide and tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA, have emerged as possible therapies for patients with HFpEF.(12-14) These agents may improve physical function and enhance quality of life by reducing adiposity, leptin levels, and RAAS activation
